FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Recurrent Diarrhea

Mytesi (crofelemer) (by Napo Pharmaceuticals), Approved December 2012
For the treatment of non-infectious diarrhea in adults with HIV/AIDS

Renal Cancer

Inlyta (axitinib) (by Pfizer), Approved January 2012
For the treatment of advanced renal cell carcinoma

Renal Cell Cancer

Afinitor (everolimus) (by Novartis), Approved March 2009
For the treatment of renal cell carcinoma

Avastin (bevacizumab) (by Genentech), Approved July 2009
For the treatment of renal cell carcinoma

Cabometyx (cabozantinib) (by Exelixis), Approved April 2016
For the treatment of advanced renal cell carcinoma

Inlyta (axitinib) (by Pfizer), Approved January 2012
For the treatment of advanced renal cell carcinoma

Lenvima (lenvatinib) (by Eisai), Approved May 2016
For the treatment of advanced renal cell carcinoma

Nexavar (sorafenib) (by Bayer/Onyx), Approved December 2005
For the Treatment of Renal Cell Carcinoma

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved November 2015
For the treatment of advanced renal cell carcinoma

Torisel (temsirolimus) (by Wyeth), Approved May 2007
For the treatment of renal cell carcinoma

Votrient (pazopanib) (by GlaxoSmithKline), Approved October of 2009
For the treatment of renal cell carcinoma

Renal Cell Carcinoma

Cabometyx (cabozantinib) (by Exelixis), Approved April 2016
For the treatment of advanced renal cell carcinoma

Inlyta (axitinib) (by Pfizer), Approved January 2012
For the treatment of advanced renal cell carcinoma

Lenvima (lenvatinib) (by Eisai), Approved May 2016
For the treatment of advanced renal cell carcinoma

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved November 2015
For the treatment of advanced renal cell carcinoma

Renal Failure

Voraxaze (glucarpidase) (by BTG International), Approved January 2012
For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function

Zemplar (by Abbott Laboratories), Approved April 1998
Treatment of secondary hyperparathyroidism associated with chronic renal failure

Respiratory Failure

Surfaxin (lucinactant) (by Discovery Laboratories), Approved March 2012
For the treatment of respiratory distress syndrome in premature infants

Respiratory Syncytial Virus (RSV) Infection

RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous) (by MedImmune), Approved January 1996
Treatment for the prevention of respiratory syncytial virus disease

Synagis (by MedImmune), Approved June 1998
Treatment for the prevention of serious lower respiratory tract disease in infants

Restless Leg Syndrome

Horizant (gabapentin enacarbil) (by GlaxoSmithKline), Approved April 2011
For the treatment of restless legs syndrome

Neupro (Rotigotine Transdermal System) (by UCB), Approved April 2012
For the treatment of Restless Legs Syndrome

Rheumatoid Arthritis

Actemra (tocilizumab) (by Genentech), Approved January 2010
For the treatment of rheumatoid arthritis

Arava (by Hoechst Marion Roussel), Approved September 1998
Treatment for Rheumatoid Arthritis

Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP) (by Pharmacia & Upjohn), Approved October 1996
Treatment for rheumatoid arthritis

Bextra (by Pharmacia, Pfizer), Approved November 2001
Oral tablet for the treatment of osteoarthritis, rheumatoid arthritis and menstrual pain

Cimzia (certolizumab pegol) (by UCB), Approved May of 2009
For the treatment of rheumatoid arthritis

Duexis (ibuprofen and famotidine) (by Horizon Pharma), Approved April 2011
For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers

Etodolac (by Royce Laboratories), Approved April 1997
Generic equivalent of Lodine

Humira (adalimumab) (by Abbott Laboratories), Approved December 2002
For the treatment of moderately to severely active rheumatoid arthritis

Kevzara (sarilumab) (by Sanofi ), Approved May 2017
For the treatment of active rheumatoid arthritis

Kineret (by Amgen), Approved November 2001
Injectable therapy for the treatment of rheumatoid arthritis

Lodine (etodolac) (by Wyeth), Approved July 1996
Treatment for rheumatoid arthritis

Naprelan (naproxen sodium) (by Elan Pharmaceuticals, Wyeth), Approved January 1996
Treatment for osteoarthritis and rheumatoid arthritis

Orencia (abatacept) (by Bristol-Myers Squibb), Approved December 2005
For the Treatment of Rheumatoid Arthritis

Rayos (prednisone) delayed-release tablets (by Horizon Pharma), Approved July of 2012
For the treatment of certain inflammatory diseases, including arthritis, COPD, asthma and psoriatic conditions

Remicade (infliximab) (by Centocor Ortho Biotech), Approved February 2002
Intravenous infusion for the treatment of rheumatoid arthritis

Remicade (infliximab) (by Centocor Ortho Biotech), Approved January 2001
For inhibiting the progression of structural damage in patients with rheumatoid arthritis

Simponi (golimumab) (by Centocor Ortho Biotech), Approved April 2009
For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Vioxx (rofecoxib) (by Merck), Approved April 2002 -- UPDATED: WITHDRAWN OCTOBER 2004
For the treatment of rheumatoid arthritis

Xeljanz (tofacitinib) (by Pfizer), Approved November 2012
For the treatment of moderately to severely active rheumatoid arthritis

Rheumatoid Arthritis (Pediatric)

Duexis (ibuprofen and famotidine) (by Horizon Pharma), Approved April 2011
For the relief of rheumatoid arthritis and osteoarthritis and prevention of gastric ulcers

Ilaris (canakinumab) (by Novartis), Approved June 2009
For the treatment of Cryopyrin-Associated Periodic Syndromes

Ilaris (canakinumab) (by Novartis), Approved May 2013
For the treatment of Systemic Juvenile Idiopathic Arthritis

Rhinitis, Allergic, Perennial

Allegra (fexofenadine hydrochloride) (by Hoechst Marion Roussel), Approved July 1996
Treatment for seasonal allergy symptoms

Astelin nasal spray (by Wallace Laboratories), Approved November 1996
Treatment for seasonal allergic rhinitis

Astepro (azelastine hydrochloride nasal spray) (by Meda Pharmaceuticals Inc), Approved October 2008
For the treatment of seasonal and perennial allergic rhinitis

Clarinex (by Schering-Plough), Approved February 2002
Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria

Clemastine fumarate syrup (by Morton Grove Pharmaceuticals), Approved March 1998
Generic equivalent of Tavist Syrup

Flonase Nasal Spray (by GlaxoSmithKline), Approved November 1997
Treatment for seasonal and perennial allergic rhinitis

Grastek (Timothy Grass Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis

Nasacort AQ (triamcinolone acetonide) Nasal Spray (by Rhone Poulenc Rorer), Approved May 1996
Treatment for allergic rhinitis

NasalCrom Nasal Spray (by Pharmacia & Upjohn), Approved April 2001
Over-the-counter nasal spray for treatment of all nasal allergy symptoms

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) (by Greer Labs), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis

Patanase (olopatadine hydrochloride) (by Alcon), Approved April 2008
For the treatment of seasonal allergic rhinitis

Qnasl (beclomethasone dipropionate) nasal aerosol (by Teva Pharmaceutical), Approved March 2012
For the treatment of seasonal and perennial allergic rhinitis

Ragwitek (Short Ragweed Pollen Allergen Extract) (by Merck), Approved April 2014
For the treatment of short ragweed pollen-induced allergic rhinitis

Rhinocort Aqua Nasal Spray (by AstraZeneca), Approved October 1999
A nasal spray containing budesonide

Tri-Nasal Spray (triamcinolone acetonide spray) (by Muro Pharmaceutical), Approved February 2000
For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older

Vancenase AQ 84 mcg Double Strength (by Schering-Plough), Approved June 1996
Treatment for allergic and non-allergic rhinitis

Veramyst (fluticasone furoate) (by GlaxoSmithKline), Approved April 2007
For the treatment of seasonal and perennial allergic rhinitis

Xyzal (levocetirizine dihydrochloride) (by UCB), Approved May 2007
For the treatment of seasonal and perennial allergic rhinitis and urticaria

Rosacea

Finacea (azelaic acid) Gel, 15% (by Berlex Laboratories), January 2003
Gel formulation for the treatment of rosacea.

Mirvaso (brimonidine) (by Galderma Labs), Approved August 2013
For the treatment of facial erythema of rosacea

Noritate (by Dermik Laboratories), Approved January 1998
Treatment for rosacea

Rhofade (oxymetazoline hydrochloride) (by Allergan), Approved January 2017
For the treatment of facial erythema associated with rosacea

Soolantra (ivermectin) cream, 1% (by Galderma Labs), Approved December 2014
For the treatment of inflammatory lesions of rosacea